 Healio | Addition of rituximab to ACVBP extended EFS, PFS Healio The addition of rituximab to doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone extended event-free survival and PFS in patients with early-stage diffuse large B-cell lymphoma, according to results from a phase 3 study. Previous ... |
